Literature DB >> 16505162

Reversal of morphine antinociceptive tolerance and dependence by the acute supraspinal inhibition of Ca(2+)/calmodulin-dependent protein kinase II.

Lei Tang1, Pradeep K Shukla, Lili X Wang, Zaijie Jim Wang.   

Abstract

Previous studies have suggested that Ca(2+)/calmodulin-dependent protein kinase II (CaMKII) can modulate opioid tolerance and dependence via its action on learning and memory. In this study, we examined whether CaMKII could directly regulate opioid tolerance and dependence. CaMKII activity was increased after the treatment with morphine (100 mg/kg s.c. or 75 mg s.c. of morphine/pellet/mouse); the effect exhibited a temporal correction with the development of opioid tolerance and dependence. In mice treated with morphine (100 mg/kg s.c.), morphine tolerance and dependence developed in 2 to 6 h. An acute supraspinal administration of KN93 [2-[N-(2-hydroxyethyl)]-N-(4-methoxybenzenesulfonyl)]amino-N-(4-chlorocinnamyl)-N-methylbenzylamine)], a CaMKII inhibitor, was able to dose-dependently reverse the already-established antinociceptive tolerance to morphine (p < 0.001 for 15-30 nmol; not significant for 5 nmol). KN92 [2-[N-(4-methoxybenzenesulfonyl)]amino-N-(4-chlorocinnamyl)-N-methylbenzylamine] (30 nmol i.c.v.), a kinase-inactive analog of KN93, did not affect opioid tolerance. Neither KN92 nor KN93 affected basal nociception or acute morphine antinociception (1-10 nmol i.c.v.). Likewise, dependence on morphine was abolished by the acute administration of KN93, but not KN92, in a dose-dependent manner. Pretreatment of mice with KN93 also prevented the development of morphine tolerance and dependence. The effect of acute CaMKII inhibition was not limited to the particular experimental model, because KN93 also acutely reversed the established opioid tolerance and dependence in mice treated with morphine (75 mg/pellet/mouse s.c.) for 6 days. Taken together, these data strongly support the hypothesis that CaMKII can act as a key and direct factor in promoting opioid tolerance and dependence. Identifying such a direct mechanism may be useful for designing pharmacological treatments for these conditions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16505162     DOI: 10.1124/jpet.105.097733

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  21 in total

Review 1.  Endogenous opiates and behavior: 2006.

Authors:  Richard J Bodnar
Journal:  Peptides       Date:  2007-09-11       Impact factor: 3.750

2.  Addiction-related genes in gambling disorders: new insights from parallel human and pre-clinical models.

Authors:  D S S Lobo; L Aleksandrova; J Knight; D M Casey; N el-Guebaly; J N Nobrega; J L Kennedy
Journal:  Mol Psychiatry       Date:  2014-09-30       Impact factor: 15.992

3.  CaMKIIα Mediates the Effect of IL-17 To Promote Ongoing Spontaneous and Evoked Pain in Multiple Sclerosis.

Authors:  Xiaoyu Hu; Fang Huang; Zaijie Jim Wang
Journal:  J Neurosci       Date:  2017-11-16       Impact factor: 6.167

4.  Haloperidol disrupts opioid-antinociceptive tolerance and physical dependence.

Authors:  Cheng Yang; Yan Chen; Lei Tang; Zaijie Jim Wang
Journal:  J Pharmacol Exp Ther       Date:  2011-03-24       Impact factor: 4.030

5.  Curcumin attenuates opioid tolerance and dependence by inhibiting Ca2+/calmodulin-dependent protein kinase II α activity.

Authors:  Xiaoyu Hu; Fang Huang; Magdalena Szymusiak; Ying Liu; Zaijie Jim Wang
Journal:  J Pharmacol Exp Ther       Date:  2014-12-16       Impact factor: 4.030

6.  AMPA receptor positive allosteric modulators attenuate morphine tolerance and dependence.

Authors:  Xiaoyu Hu; Xuebi Tian; Xiao Guo; Ying He; Haijun Chen; Jia Zhou; Zaijie Jim Wang
Journal:  Neuropharmacology       Date:  2018-04-25       Impact factor: 5.250

7.  Ca2+/calmodulin-dependent protein kinase II alpha is required for the initiation and maintenance of opioid-induced hyperalgesia.

Authors:  Yan Chen; Cheng Yang; Zaijie Jim Wang
Journal:  J Neurosci       Date:  2010-01-06       Impact factor: 6.167

8.  Orally administered nanocurcumin to attenuate morphine tolerance: comparison between negatively charged PLGA and partially and fully PEGylated nanoparticles.

Authors:  Hao Shen; Xiaoyu Hu; Magdalena Szymusiak; Zaijie Jim Wang; Ying Liu
Journal:  Mol Pharm       Date:  2013-11-19       Impact factor: 4.939

9.  Acute inhibition of Ca2+/calmodulin-dependent protein kinase II reverses experimental neuropathic pain in mice.

Authors:  Yan Chen; Fang Luo; Cheng Yang; Chelsea M Kirkmire; Zaijie Jim Wang
Journal:  J Pharmacol Exp Ther       Date:  2009-05-28       Impact factor: 4.030

10.  Role of D₁/D₂ dopamin receptors antagonist perphenazine in morphine analgesia and tolerance in rats.

Authors:  Ercan Ozdemir; Ihsan Bagcivan; Sinan Gursoy
Journal:  Bosn J Basic Med Sci       Date:  2013-05       Impact factor: 3.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.